dorzolamide hydrochloride (+) timolol maleate
DrugDorzolamide hydrochloride 1% + timolol 0.5%, 8-week
NCT Number: NCT00449956
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
timolol maleate 0.5%, 8-week
dorzolamide hydrochloride 1%, 8-week
Time frame: 8 weeks
Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)
Time frame: 8 Weeks
Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)
Time frame: 8 weeks
Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)
Merck Sharp & Dohme LLC
Industry
Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07592988
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT07592923
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07763288
Blind Eye, Blindness
Nonthaburi, Thailand
View Trial Details